TriangleFOR PATIENTS · SOURCE READING
Targeted therapy for hormone receptor–positive breast cancer
Source: Targeted Therapy for Breast Cancer, National Cancer Institute.
Source updated: Not stated in this source · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
NCI patient treatment article for this disease Exact source article; not a clinically reviewed indication or current-standard recommendation.
Context: Targeted Therapy for Breast Cancer
Targeted therapy for hormone receptor–positive breast cancer
In hormone receptor–positive (HR positive) breast cancer, the breast cancer cells have estrogen or progesterone receptors, or both.
The following targeted therapy drugs may be used alone or with other treatments, particularly hormone therapy:
abemaciclib
Source links and citations
alpelisib
Source links and citations
everolimus
Source links and citations
palbociclib
Source links and citations
ribociclib
Source links and citations
sacituzumab govitecan
Source links and citations
These drugs may be given with hormone therapy, such as an aromatase inhibitor (such as anastrozole, letrozole, or exemestane) or fulvestrant or letrozole, to treat hormone receptor–positive, HER2-negative breast cancer. Learn more about Hormone Therapy for Breast Cancer.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice